| Literature DB >> 32549098 |
Orcun Gurbuz1, Gencehan Kumtepe1, Hakan Ozkan2, Ilker Hasan Karal3, Yusuf Velioglu4, Abdulkadir Ercan5, Ahmet Yüksel4, Serdar Ener6.
Abstract
OBJECTIVE: To investigate the predictive value of preoperative neutrophil-lymphocyte ratio (NLR) for long-term major adverse cardiac and cerebrovascular events (MACCE), which have not yet been well described, in patients undergoing coronary artery bypass grafting (CABG).Entities:
Keywords: Coronary Artery Bypass; Lymphocytes; Myocardial Infarction; Neutrophils; Percutaneous Coronary Intervention; Stroke
Year: 2020 PMID: 32549098 PMCID: PMC7299596 DOI: 10.21470/1678-9741-2018-0362
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Effects of multiple variables on MACCE in Cox regression analysis
| Characteristics | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Demographics | ||||||
| Age (years) | 1.050 | 1.024-10.76 | <0.001 | |||
| Male sex | 1.215 | 0.702-2.103 | 0.48 | |||
| Laboratory parameters | ||||||
| WBC | 0.997 | 0.918-1.083 | 0.99 | |||
| Neutrophil | 1.120 | 1.026-1.222 | 0.011 | |||
| Lymphocyte | 0.461 | 0.333-0.638 | <0.001 | |||
| NLR | 1.109 | 1.063-1.156 | <0.001 | 1.087 | 1.026-1.151 | 0.004 |
| CRP | 1.045 | 0.974-1.122 | 0.21 | |||
| Hg | 0.922 | 0.833-1.020 | 0.92 | |||
| CrCL | 0.991 | 0.983-0.998 | 0.014 | |||
| Risk factors and medical history | ||||||
| Obesity | 1.348 | 0.836-2.175 | 0.22 | |||
| EuroSCORE | 1.182 | 1.094-1.277 | <0.001 | |||
| USAP | 0.923 | 0.571-1.492 | 0.74 | |||
| History of MI (>21 days) | 1.723 | 1.101-2.698 | 0.017 | |||
| History of PCI | 1.187 | 0.630-2.235 | 0.59 | |||
| Current smoker | 0.795 | 0.501-1.261 | 0.32 | |||
| Family history of CAD | 0.489 | 0.270-0.887 | 0.019 | 0.409 | 0.180-0.928 | 0.032 |
| IDDM | 2.280 | 1.205-4.313 | 0.011 | |||
| Dyslipidaemia | 1.092 | 0.667-1.785 | 0.72 | |||
| Hypertension | 2.150 | 1.344-3.427 | 0.001 | 2.575 | 1.416-4.683 | 0.002 |
| COPD | 1.686 | 0.812-3.504 | 0.16 | |||
| Asymptomatic carotid stenosis | 2.073 | 1.258-3.416 | 0.004 | |||
| PVD | 2.187 | 1.109-4.311 | 0.024 | |||
| History of stroke | 1.997 | 0.807-4.942 | 0.13 | |||
| Estimated LVEF 30-49% | 1.006 | 0.606-1.671 | 0.98 | |||
| Estimated LVEF <30% | 1.831 | 0.881-3.806 | 0.1 | |||
| Mild valvular insufficiency | 1.378 | 0.827-2.298 | 0.21 | |||
| Angiographic findings | ||||||
| LMCA stenosis | 1.863 | 1.134-3.063 | 0.014 | |||
| Average number of vessel disease | 1.491 | 0.978-2.272 | 0.06 | |||
| Three-vessel disease | 1.736 | 1.028-2.931 | 0.039 | |||
| Perioperative data | ||||||
| Number of distal anastomosis | 1.190 | 0.932-1.518 | 0.16 | |||
| Incomplete revascularization | 0.824 | 0.333-2.037 | 0.67 | |||
| Endarterectomy | 1.233 | 0.734-2.072 | 0.42 | |||
| CPB time | 1.012 | 0.988-1.036 | 0.33 | |||
| Perioperative IABP | 7.660 | 2.415-24.298 | 0.001 | |||
| Perioperative inotropic agent | 2.962 | 1.705-5.147 | <0.001 | |||
| Perioperative AF | 1.670 | 0.916-3.045 | 0.09 | |||
| Perioperative MI | 1.098 | 0.505-2.387 | 0.81 | |||
| Prolonged respiratory period | 1.520 | 1.137-2.032 | 0.005 | 5.438 | 1.723-17.163 | 0.004 |
| Duration of ICU stay | 1.008 | 0.999-1.017 | 0.08 | |||
| Pulmonary complication | 1.230 | 0.775-1.925 | 0.38 | |||
| Perioperative renal failure | 2.072 | 0.188-3.611 | 0.01 | 3.028 | 1.089-2.048 | 0.026 |
| Cerebrovascular complication | 2.490 | 1.318-4.704 | 0.005 | |||
| Blood transfusion | 1.281 | 1.137-1.442 | <0.001 | |||
| Length of hospital stay | 1.353 | 1.206-1.518 | <0.001 | |||
Statistically significant difference. AF=atrial fibrillation; CAD=coronary artery disease; CI=confidence interval; COPD=chronic obstructive pulmonary disease; CPB=cardiopulmonary bypass; CrCL=creatinine clearance; CRP=C-reactive protein; EuroSCORE=European System for Cardiac Operative Risk Evaluation; Hg=haemoglobin level; IABP=intra-aortic balloon pump; ICU=intensive care unit; IDDM=insulin-dependent diabetes mellitus; LMCA=left main coronary artery; LVEF=left ventricular ejection fraction; MACCE=major cardiac and cerebrovascular event; MI=myocardial infarction; NLR=neutrophil-lymphocyte ratio; OR=odds ratio; PCI=percutaneous coronary intervention; PVD=peripheral vascular disease; USAP=unstable angina pectoris; WBC=white blood cell count
Effects of multiple variables on MACCE according to EuroSCORE Risk Score in Cox regression analysis.
| EuroSCORE ≤2 | EuroSCORE 3-5 | EuroSCORE ≥6 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | OR | 95% CI | ||||
| Laboratory parameters | |||||||||
| NLR | 1.113 | 1.048-1.183 | <0.001 | 1.161 | 1.060-1.273 | 0.001 | 1.127 | 1.012-1.255 | 0.029 |
| WBC | 0.936 | 0.779-1.125 | 0.48 | 1.105 | 0.889-1.159 | 0.82 | 1.023 | 0.919-1.139 | 0.67 |
| Lymphocyte | 0.231 | 0.116-0.461 | <0.001 | 0.606 | 0.355-1.035 | 0.06 | 0.575 | 0.347-0.953 | 0.032 |
| Neutrophil | 1.143 | 0.916-1.426 | 0.23 | 1.175 | 1.000-1.380 | 0.05 | 1.070 | 0.955-1.198 | 0.24 |
| CrCL | 0.993 | 0.979-1.007 | 0.99 | 0.989 | 0.975-1.003 | 0.11 | 0.993 | 0.982-1.005 | 0.27 |
| Risk factors and medical history | |||||||||
| Age | 1.025 | 0.965-1.090 | 0.41 | 1.019 | 0.974-1.067 | 0.41 | 1.059 | 1.009-1.112 | 0.02 |
| History of MI | 2.016 | 0.740-5.494 | 0.17 | 1.426 | 0.666-3.057 | 0.36 | 1.213 | 0.616-2.387 | 0.57 |
| Family history of CAD | 0.635 | 0.234-1.722 | 0.37 | 0.594 | 0.240-1.469 | 0.26 | 0.236 | 0.57-0.984 | 0.047 |
| Hypertension | 5.241 | 1.773-15.490 | 0.003 | 1.899 | 0.877-4.115 | 0.1 | 1.532 | 0.772-3.042 | 0.22 |
| IDDM | 2.208 | 0.653-7.466 | 0.2 | 4.918 | 1.979-12.219 | 0.001 | 0.996 | 0.305-3.254 | 0.99 |
| Asymptomatic carotid stenosis | 0.048 | 0-90770.430 | 0.68 | 2.408 | 1.088-5.325 | 0.03 | 1.294 | 0.658-2.546 | 0.45 |
| PVD | 10.595 | 2.443-45.944 | 0.002 | 1.496 | 0.421-5.317 | 0.53 | 1.158 | 0.409-3.283 | 0.78 |
| Angiographic findings | |||||||||
| LMCA stenosis | 2.427 | 0.948-6.211 | 0.065 | 2.211 | 0.974-5.021 | 0.05 | 1.200 | 0.545-2.641 | 0.65 |
| Three-vessel disease | 1.862 | 0.687-5.049 | 0.22 | 1.168 | 0.515-2.653 | 0.71 | 1.898 | 0.829-4.349 | 0.13 |
| Perioperative data | |||||||||
| Perioperative IABP | - | - | - | 4.871 | 0.661-35.918 | 0.12 | 6.150 | 1.463-25.854 | 0.013 |
| Perioperative inotropic agent | 6.521 | 0.873-48.738 | 0.06 | 1.955 | 0.590-6.478 | 0.27 | 2.174 | 1.111-4.254 | 0.023 |
| Prolonged respiratory period | - | - | - | 5.369 | 1.260-22.883 | 0.023 | 2.010 | 0.477-8.467 | 0.34 |
| Perioperative renal failure | 0.046 | 0-244.968 | 0.48 | 3.861 | 1.800-8.282 | 0.001 | 2.679 | 1.361-5.270 | 0.004 |
| Cerebrovascular complication | 1.358 | 0.183-10.102 | 0.76 | 4.541 | 1.703-12.109 | 0.002 | 1.211 | 0.470-3.122 | 0.69 |
| Blood transfusion | 1.104 | 0.730-1.670 | 0.63 | 1.357 | 1.147-1.606 | <0.001 | 1.094 | 0.899-1.331 | 0.37 |
| Length of hospital stay | 1.125 | 0.697-1.816 | 0.63 | 1.075 | 0.914-1.264 | 0.38 | 1.111 | 1.007-1.224 | 0.035 |
Statistically significant difference. CAD=coronary artery disease; CI=confidence interval; CrCL=creatinine clearance; EuroSCORE=European System for Cardiac Operative Risk Evaluation; IABP=intra-aortic balloon pump; IDDM=insulin-dependent diabetes mellitus; LMCA=left main coronary artery; MACCE=major cardiac and cerebrovascular event; MI=myocardial infarction; NLR=neutrophil-lymphocyte ratio; OR=odds ratio; PVD=peripheral vascular disease; WBC=white blood cell count
Baseline demographic and clinical parameters according to NLR quartiles.
| Characteristics | Overall | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | |
|---|---|---|---|---|---|---|
| n=751 | n=189 | n=188 | n=187 | n=187 | ||
| 0.17-1.83 | 1.84-2.47 | 2.48-3.23 | ≥ 3.24 | |||
| Laboratory parameters | ||||||
| NLR | 3.04±2.69 | 1.3 ± 0.34 | 2.05 ± 0.19 | 2.87 ± 0.2 | 5.94 ± 4.07 | <0.001 |
| WBC (×109/L) | 7.74±2.65 | 7.37±2.8 | 7.74±2.26 | 7.53±2.8 | 8.34±2.62 | <0.001 |
| CRP | 1.81±3.12 | 1.11±2.16 | 1.5±2.71 | 2.41±3.29 | 2.64±4.19 | 0.018 |
| Hg | 11.05±2.31 | 10.90±2.34 | 11.07±2.31 | 11.11±2.35 | 11.10±2.26 | 0.69 |
| CrCL | 101.98±35.63 | 93.62±35.27 | 101.48±33.72 | 106.19±35.76 | 106.84±36.47 | 0.002 |
| Demographics | ||||||
| Age (years) | 62.34±9.43 | 61.41±9.52 | 61.52±9.72 | 61.88±9.42 | 64.57±8.76 | 0.003 |
| Male | 577 (76.8) | 150 (79.4) | 136 (72.3) | 187 (80.7) | 140 (74.9) | 0.18 |
| Risk factors and medical history | ||||||
| EuroSCORE | 3.61±2.52 | 3.64±2.48 | 3.46±2.49 | 3.50±2.49 | 3.83±2.55 | 0.41 |
| CCS | 2.52±1.24 | 2.52±1.26 | 2.56±1.26 | 2.50±1.28 | 2.50±1.15 | 0.92 |
| USAP | 238 (31.7) | 62 (32.8) | 62 (33) | 63 (33.7) | 51 (27.3) | 0.51 |
| Obesity (BMI ≥30) | 225 (33.3) | 48 (25.4) | 63 (33.5) | 58 (31) | 56 (29.9) | 0.53 |
| Current smoker | 298 (39.7) | 90 (47.6) | 68 (36.2) | 88 (47.1) | 52 (27.8) | <0.001 |
| Hypertension | 371 (49.4) | 87 (46) | 90 (47.9) | 96 (51.3) | 98 (52.4) | 0.57 |
| Dyslipidaemia | 196 (26.1) | 51 (27) | 49 (26.1) | 46 (24.6) | 50 (26.7) | 0.95 |
| Family history of CAD | 206 (27.4) | 53 (28) | 55 (29.3) | 59 (31.6) | 39 (20.9) | 0.11 |
| IDDM | 54 (7.2) | 10 (5.3) | 9 (4.8) | 12 (6.4) | 23 (12.3) | 0.018 |
| COPD | 50 (6.7) | 10 (5.3) | 12 (6.4) | 9 (4.8) | 19 (10.2) | 0.15 |
| History of stroke | 28 (3.7) | 8 (4.2) | 7 (3.7) | 5 (2.7) | 8 (4.3) | 0.32 |
| PVD | 34 (4.5) | 12 (6.3) | 3 (1.6) | 6 (3.2) | 13 (7) | 0.027 |
| Asymptomatic carotid stenosis | 115 (15.3) | 35 (18.5) | 26 (13.8) | 24 (12.8) | 30 (16) | 0.42 |
| History of MI | 224 (29.8) | 59 (31.2) | 51 (27.1) | 61 (32.6) | 53 (28.3) | 0.63 |
| Estimated LVEF 30-49% | 191 (25.4) | 46 (24.3) | 51 (27.1) | 53 (28.3) | 41 (21.9) | 0.97 |
| Estimated LVEF <30% | 48 (6.4) | 13 (6.9) | 9 (4.8) | 9 (4.8) | 17 (9.1) | 0.27 |
| Mild mitral insufficiency | 79 (10.5) | 19 (10.1) | 17 (9) | 20 (10.6) | 23 (12.3) | 0.62 |
| Previous PCI | 73 (9.7) | 23 (12.2) | 15 (8) | 18 (9.6) | 20 (10.7) | 0.56 |
| Angiographic findings | ||||||
| Number of vessel disease | 2.61±0.6 | 2.6±0.59 | 2.53±0.68 | 2.64±0.55 | 2.67±0.58 | 0.18 |
| LMCA stenosis | 125 (16.6) | 28 (14.8) | 31 (16.5) | 30 (16) | 36 (19.3) | 0.7 |
| Three-vessel disease | 510 (67.9) | 125 (66.1) | 120 (63.8) | 128 (68.4) | 137 (73.3) | 0.24 |
Statistically significant difference. Values are presented as mean ± standard deviation or number (%), where appropriate. BMI=body mass index; CAD=coronary artery disease; COPD=chronic obstructive pulmonary disease; CrCL=creatinine clearance; CRP=C-reactive protein; CCS=Canadian Cardiovascular Society grading of angina; EuroSCORE=European System for Cardiac Operative Risk Evaluation; Hg=haemoglobin level; IDDM=insulin-dependent diabetes mellitus; LMCA=left main coronary artery; LVEF=left ventricular ejection fraction; MI=myocardial infarction; NLR=neutrophil-lymphocyte ratio; PCI=percutaneous coronary intervention; PVD=peripheral vascular disease; USAP=unstable angina pectoris; WBC=white blood cell count
Perioperative and early postoperative characteristics of the patients stratified by NLR quartiles.
| Characteristics | Overall | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | |
|---|---|---|---|---|---|---|
| n=751 | n=189 | n=188 | n=187 | n=187 | ||
| 0.17-1.83 | 1.84-2.47 | 2.48-3.23 | ≥ 3.24 | |||
| Operative data | ||||||
| Number of distal anastomoses | 3.41±0.88 | 3.40±0.86 | 3.29±0.86 | 3.48±0.88 | 3.47±0.92 | 0.24 |
| Incomplete revascularization | 136 (18.1) | 31 (16.4) | 38 (20.2) | 34 (18.2) | 33 (17.6) | 0.81 |
| Number of grafted LAD | 1.65±0.55 | 1.66±0.5 | 1.63±0.58 | 1.65±0.56 | 1.67±0.56 | 0.48 |
| Number of grafted Cx | 0.99±0.65 | 0.97±0.57 | 0.96±0.67 | 1±0.69 | 1.03±0.65 | 0.64 |
| Number of grafted RCA | 0.75±0.53 | 0.75±0.54 | 0.68±0.5 | 0.8±0.56 | 0.76±0.51 | 0.23 |
| Endarterectomy | 69 (9.2) | 20 (10.6) | 15 (8) | 18 (9.6) | 16 (8.6) | 0.82 |
| CPB time | 87.83±26.5 | 87.45±26.68 | 85.92±30.57 | 85.1±21.55 | 94.52±26.47 | 0.76 |
| Postoperative data | ||||||
| Hospital stay (days) | 5.84±2.71 | 5.70±1.59 | 5.83±2.79 | 5.62±1.94 | 6.22±3.91 | 0.21 |
| Prolonged mechanical ventilation time | 19 (2.5) | 2 (1.1) | 3 (1.6) | 4 (2.1) | 10 (5.3) | 0.038 |
| Intensive care unit stay (h) | 22.8±45.81 | 19.15±6.45 | 22.02±25.25 | 20.55±16.79 | 29.54±86.21 | 0.007 |
| Drainage (ml/24 h) | 511.63±298.83 | 508.65±304.34 | 500±252.55 | 496.9±308.31 | 544.71±330.99 | 0.7 |
| Blood transfusion (unit) | 1.35±1.54 | 1.24±1.39 | 1.23±1.58 | 1.25±1.42 | 1.69±1.71 | 0.002 |
| cTnI (ng/ml) | 2.48±2.99 | 2.02±2.13 | 2.33±2.92 | 2.6±3.52 | 2.89±3.16 | 0.09 |
| Perioperative inotropic support | 42 (5.6) | 7 (3.7) | 9 (4.8) | 8 (4.3) | 18 (9.6) | 0.048 |
| Perioperative IABP | 7 (0.9) | 1 (0.5) | 2 (1.1) | 1 (0.5) | 3 (1.6) | 0.65 |
| Perioperative NSTEMI | 62 (8.3) | 20 (10.6) | 14 (7.4) | 15 (8) | 16 (8.6) | 0.72 |
| Early STEMI (<30 days) | 6 | 1 (0.5) | 0 | 1 (0.5) | 4 (2.1) | 0.1 |
| Perioperative AF | 94 (12.5) | 16 (8.5) | 27 (14.4) | 24 (12.8) | 27 (14.4) | 0.25 |
| Perioperative renal failure | 103 (13.7) | 25 (13.2) | 20 (10.6) | 29 (15.5) | 29 (15.5) | 0.46 |
| Pulmonary complication | 21 (2.8) | 4 (2.1) | 6 (3.1) | 3 (1.6) | 8 (4.3) | 0.4 |
| Reintubation/NIMV | 11 (1.4) | 1 (0.5) | 3 (1.6) | 0 | 7 (3.7) | 0.013 |
| Neurological complication | 52 (6.9) | 14 (7.4) | 9 (8.4) | 13 (7) | 16 (8.4) | 0.53 |
| Encephalopathy | 22 (2.9) | 4 (2.1) | 6 (3.2) | 4 (2.1) | 8 (4.3) | 0.55 |
| TIA | 28 (3.7) | 11 (5.8) | 3 (1.6) | 8 (4.3) | 6 (3.2) | 0.17 |
| Stroke | 5 (0.7) | 0 | 0 | 1 (0.5) | 4 (2.1) | 0.034 |
| Mediastinitis | 5 (0.7) | 1 (0.5) | 0 | 2 (1.1) | 2 (1.1) | 0.16 |
| Early reoperation | 12 (2.3) | 4 (2.1) | 3 (1.6) | 2 (1.1) | 3 (1.6) | 0.49 |
| Early reoperation due to bleeding | 10 (1.3) | 3 (1.6) | 3 (1.6) | 2 (1.1) | 2 (1.1) | 0.94 |
| Early rehospitalisation (<30 days) | 48 (6.4) | 15 (7.9) | 6 (3.2) | 14 (7.5) | 13 (7) | 0.06 |
| Mortality (<30 days) | 8 (1.1) | 1 (0.5) | 1 (0.5) | 0 | 6 (3.2) | 0.011 |
| MACCE (<30 days) | 19 (2.5) | 4 (2.1) | 2 (1.1) | 4 (2.1) | 9 (4.8) | 0.12 |
Statistically significant difference. Values are presented as mean ± standard deviation or number (%), where appropriate. AF=atrial fibrillation; CPB=cardiopulmonary bypass; Cx=circumflex coronary artery; cTnI=cardiac troponin I; FFP=fresh frozen plasma; IABP=intra-aortic balloon pump; LAD=left anterior descending coronary artery; LIMA=left internal mammary artery; MACCE=major adverse cardiac and cerebrovascular event; MI=myocardial infarction; NIMV=non-invasive mechanical ventilation; NSTEMI=non-ST elevation myocardial infarction; RCA=right coronary artery; STEMI= ST elevation myocardial infarction; TIA=transient ischemic attack
Long-term outcomes of the patients, according to NLR quartiles.
| Characteristics | Overall | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | |
|---|---|---|---|---|---|---|
| n=751 | n=189 | n=188 | n=187 | n=187 | ||
| 0.17-1.83 | 1.84-2.47 | 2.48-3.23 | ≥3.24 | |||
| Mean follow-up time (months) | 78.2±15.79 | 80.83±12.13 | 80.3±12.13 | 79.37±14.36 | 72.25±20.65 | <0.001 |
| MACCE-free survival | 76.03±18.35 | 80.03±13.41 | 79.83±13.81 | 76.66±18.33 | 67.32±23.33 | <0.001 |
| MACCE (1 year) | 23 (3.1) | 1 (0.5) | 2 (1.1) | 7 (3.7) | 13 (7) | 0.001 |
| MACCE (3 years) | 42 (5.5) | 3 (1.6) | 7 (4.3) | 8 (4.3) | 24 (12.8) | <0.001 |
| MACCE (7.8 years) | 87 (11.6) | 11 (5.8) | 7 (3.7) | 20 (10.8) | 49 (26.5) | <0.001 |
| STEMI | 31 (4.1) | 3 (1.6) | 3 (1.6) | 7 (3.7) | 19 (10.2) | <0.001 |
| Stroke | 23 (3.1) | 3 (1.6) | 3 (1.6) | 4 (2.1) | 13 (7) | 0.005 |
| Late reintervention | 34 (4.6) | 3 (1.6) | 0 | 11 (5.8) | 20 (10.7) | <0.001 |
| PCI | 30 (4) | 3 (1.6) | 0 | 10 (5.3) | 17 (9.1) | <0.001 |
| Redo-CABG | 2 (0.3) | 0 | 0 | 0 | 2 (1.1) | 0.1 |
| Pacemaker | 2 (0.3) | 0 | 0 | 1 (0.5) | 1 (0.5) | 0.56 |
| All-cause mortality | 60 (8) | 8 (4.2) | 9 (4.8) | 15 (8) | 28 (15) | <0.001 |
| Cardiovascular mortality | 40 (5.3) | 3 (1.6) | 5 (2.7) | 8 (4.3) | 25 (13.4) | <0.001 |
| Non-cardiovascular mortality | 19 (2.6) | 5 (2.6) | 4 (2.1) | 7 (3.7) | 3 (1.6) | 0.62 |
Statistically significant difference. Values are represented as mean ± standard deviation and number (%), where appropriate. CABG=coronary artery bypass grafting; MACCE=major adverse cardiac and cerebrovascular event; PCI=percutaneous coronary intervention; STEMI=ST elevation myocardial infarction
Fig. 1Kaplan-Meier estimates of survival free of cardiovascular death, stroke, myocardial infarction and repeated coronary revascularization (P<0.001 by the log-rank test). Q=quartile
Fig. 2ROC curve analysis. The diagonal represents the no-effect line (AUC=0.50), with curves above this line representing increasing diagnostic accuracy. NLR accurately predicted MACCE (AUC=0.74). The circle represents the optimal cut-off to predict MACCE with a sensitivity of 50.6% and specificity of 92%. AUC=area under the curve
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
| ACT | = Activated clotting time | ICU | = Intensive care unit | |
| CABG | = Coronary artery bypass grafting | LMCA | = Left main coronary artery | |
| CAD | = Coronary artery disease | MACCE | = Major adverse cardiac and cerebrovascular events | |
| COPD | = Chronic obstructive pulmonary disease | NLR | = Neutrophil-lymphocyte ratio | |
| CPB | = Cardiopulmonary bypass | ON-BH CABG | = On-pump beating-heart CABG | |
| CrCl | = Creatinine clearance | PCI | = Percutaneous cardiac intervention | |
| CTnI | = Cardiac troponin I | PVD | = Peripheral vascular disease | |
| EuroSCORE | =European System for Cardiac Operative Risk Evaluation | ROC | = Receiver operating characteristic | |
| IABP | = Intra-aortic balloon pumping | STEMI | = ST elevation myocardial infarction | |
| Author's roles & responsibilities | |
|---|---|
| OG | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| GK | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved |
| HO | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved |
| IHK | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved |
| YV | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| AE | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content |
| AY | Drafting the work or revising it critically for important intellectual content |
| SE | Drafting the work or revising it critically for important intellectual content |